Abstract
Vasa vasorum nourish the atherosclerotic plaque, with an organized system regulated by sympathetic and hormonal stimuli. Plaque neovascularization is recognized as an important contributor of destabilization of atheromas, leading to symptomatic atherosclerosis and increased vulnerability of the plaque. These emerging data suggest that the early recognition and imaging of the vasa vasorum may lead to the early identification of the vulnerable plaque and the vulnerable patient. In coronary artery disease, the inhibition of plaque angiogenesis may constitute a valuable therapeutic approach toward plaque stabilization. Several potential inhibitors of angiogenesis, with different pathophysiological mechanisms of action, have been tested for this reason. These agents can be generally separated into those that can be applied systematically and into those that have a local effect on the vulnerable plaque.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Fleiner M, Kummer M, et al. (2004) Arterial neovascularization and inflammation in vulnerable patients: Early and late signs of symptomatic atherosclerosis. Circulation 110:2843–2850.
Ganaha F, Kao EY, et al. (2004) Stent-based controlled release of intravascular angiostatin to limit plaque progression and in-stent restenosis. J Vasc Interv Radiol 15:601–608.
Herrmann J, Lerman LO, et al. (2001) Coronary vasa vasorum neovascularization precedes epicardial endothelial dysfunction in experimental hypercholesterolemia. Cardiovasc Res 51:762–766.
Hurwitz H, Fehrenbacher L, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342.
Kamat BR, Galli SJ, et al. (1987) Neovascularization and coronary atherosclerotic plaque: Cinematographic localization and quantitative histologic analysis. Hum Pathol 18:1036–1042.
Kerwin W, Hooker A, et al. (2003) Quantitative magnetic resonance imaging analysis of neovasculature volume in carotid atherosclerotic plaque. Circulation 107:851–856.
Kerwin WS, Oikawa M, et al. (2008) MR imaging of adventitial vasa vasorum in carotid atherosclerosis. Magn Reson Med 59:507–514.
Moreno PR, Purushothaman KR, et al. (2004) Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation 110:2032–2038.
Moreno PR, Purushothaman KR, et al. (2006) Neovascularization in human atherosclerosis. Circulation 113:2245–2252.
Moulton KS, Heller E, et al. (1999) Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 99:1726–1732.
O’Brien KD, McDonald TO, et al. (1996) Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. Circulation 93:672–682.
O’Malley SM, Vavuranakis M, et al. (2005) Intravascular ultrasound-based imaging of vasa vasorum for the detection of vulnerable atherosclerotic plaque. Med Image Comput Comput Assist Interv 8:343–351.
Rodriguez JA, Nespereira B, et al. (2005) Vitamins C and E prevent endothelial VEGF and VEGFR-2 overexpression induced by porcine hypercholesterolemic LDL. Cardiovasc Res 65:665–73.
Stefanadis C, Toutouzas K, et al. (2006) First experimental application of bevacizumab-eluting PC coated stent for inhibition of vasa vasorum of atherosclerotic plaque: angiographic results in a rabbit atheromatic model. Hellenic J Cardiol 47:7–10.
Stefanadis C, Toutouzas K, et al. (2007) Inhibition of plaque neovascularization and intimal hyperplasia by specific targeting vascular endothelial growth factor with bevacizumab-eluting stent: An experimental study. Atherosclerosis 195:269–276.
Stefanadis C, Toutouzas K, et al. (2008) Avastin-eluting stent: Long-term angiographic and clinical follow up. Hellenic J Cardiol 49:188–190.
Stefanadis C, Toutouzas K, et al. (2007) First-in-man study with bevacizumab-eluting stent: A new approach for the inhibition of atheromatic plaque neovascularization Eurointerv 3:460–464.
Vavuranakis M, Kakadiaris IA, et al. (2008) A new method for assessment of plaque vulnerability based on vasa vasorum imaging, by using contrast-enhanced intravascular ultrasound and differential image analysis. Int J Cardiol 130:23–29.
Wilson SH, Herrmann J, et al. (2002) Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering. Circulation 105:415–8.
Winter PM, Neubauer AM, et al. (2006) Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol 26:2103–2109.
Yang J, Hawworth L, et al. (2003) A randomised trial of bevacizumab, an antivascular endothelial growth antibody for metastatic renal cancer. N Engl J Med 349:427–34.
Zhu XY, Rodriguez-Porcel M, et al. (2004) Antioxidant intervention attenuates myocardial neovascularization in hypercholesterolemia. Circulation 109:2109–15.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Toutouzas, K., Synetos, A., Stefanadis, C. (2010). Angiogenic Approaches for Inhibition of Plaque Destabilization in Atherosclerosis. In: Slevin, M. (eds) Therapeutic Angiogenesis for Vascular Diseases. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-9495-7_11
Download citation
DOI: https://doi.org/10.1007/978-90-481-9495-7_11
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-9494-0
Online ISBN: 978-90-481-9495-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)